Cancer, one of the most important problems of our time, is expected to become a more destructive force within 20 years. The number of patients living with cancer in Turkey in 2015, 537 thousand, 734 thousand in 2020, while in 2030 it is estimated to rise to 1.3 million people. The most common cancers in men are the lung and prostate, the most common in women breast cancer continues to be. Pfizer Turkey Medical Oncology Leader Esra smoky, on Pfizer's risk of developing breast cancer as one out of every eight women is constantly working to develop new treatments, he said.
Pfizer Onkoloj is a key member of the collaborative effort of the different stakeholders struggling with cancer, such as the patient, patient relatives and doctors, to defeat cancer, to respond to the needs of current and future cancer patients and to offer them the best treatment as well as patients.
Pfizer, patients with innovative treatment to prolong their life span that is working in collaboration with all stakeholders Pfizer Oncology Medical Leader Turkey Esra smoky, Pfizer's innovative products, only in 2014 European He emphasized that more than 47,000 patients in different types of cancer have been used in the treatment of cancer.
"Thanks to our hopeful innovations, an area that has not undergone significant development for more than 10 years, breast cancer treatment We have developed. In addition, 14 biological products and small molecule phase I-III studies for kidney, lung cancers and hematological cancers are continuing. "
The power to turn cancer treatment is immunoonooncology!
One of Pfizer's top priority areas is immunology. Esra Dumanli, "As Pfizer, we are working very hard to develop the science of immunoonoonology. We believe that there will be immunotherapy in the future to restore cancer treatment. "
"Innovative approach to cancer therapy and innovative drugs provide doctors with a new foundation in which to build next-generation developments with more choices and researchers to reach the best result in each patient. Thanks to the steady development over the past 60 years on blood cancers, one of the most common cancers in Europe, Hodgkin's disease, has a chance of survival of 5 years to 80.8%, which is a great example. "
New priority in cancer treatment: "personalized treatment"
Dr. Pfizer noted that oncology aims to understand the complex nature of each patient and each cancer type and to develop more effective therapies with this approach. Esra Dumanli continued: "At the beginning of the most important issues in cancer treatment in the world, instead of giving each patient a standard treatment, treatment for each individual is aimed at differentiating treatment and adding more value to the life of the patient.
As Pfizer Oncology, we will continue to work with our physicians in order to reach the illness of "personality-specific" medicines by taking this priority into consideration. It is our primary goal to do research to develop possible treatments and to increase the benefits seen from these treatments. We currently have medicines for the treatment of kidney cancer and lung cancer. Two areas where new treatments are needed; new treatments for breast cancer and hematological cancers are being developed, some of them USA and has been approved in Europe. "
1.7 million women are diagnosed with breast cancer every year worldwide
Dr. Striking attention to advanced stage, metastatic breast cancer. Esra Dumanli said: "Pfizer is working quickly to develop innovative therapies for breast cancer. Mammary cancer is generally diagnosed at an early stage, 9% of the patients are metastatic at the time of diagnosis.
Approximately four out of all breast cancer patients have metastatic disease when assessed with relapse patients. As Pfizer, we are working on new mechanisms and innovative therapies that will delay the progression of the disease in a large proportion of these women whose disease is in the metastatic phase. "
What is breast cancer?
Breast Cancer is the most common cancer type among women worldwide. There is a risk that every 8 females for life will get cancer. In the first 30 percent of women diagnosed at early stages of breast cancer, progressive or metastatic disease develops over time.
Some of the risk factors for breast cancer include age (with risk at age and over 55 years), family history, gene mutation, reproductive history (menstruation before 12 years of age or menopause after 55 years of age, after the first gestational age of 30 years, women may slightly increase the risk of breast cancer.) Only 7-9% of breast cancers are familial transitions. Breast cancer and male breast cancer at a young age, especially on the mother's side, may indicate a familial transition.
What is the most common indication of breast cancer?
The most common indication of breast cancer is the formation of a new lump or mass in the mammary gland. Other possible signs include partial or complete swelling in the breast, irritation or depression in the breast, inward of the nipple, or discharge from the nipple. After breast cancer is diagnosed, it can be classified up to the fourth stage (metastatic or advanced) from the first stage (early stage breast cancer). Although breast cancer can spread to almost every region of the body, it usually spreads to bones, lungs and liver. Clinical breast examination, mammography, ultrasound, MR or biopsy can be used for breast cancer. Tumor testing for certain markers, such as the HER2 protein, may help determine the likelihood of cancer spread and the best treatment for the patient.
How is breast cancer treated?
Systemic treatment options for metastatic breast cancer include chemotherapy, hormone therapy, or targeted therapies. Targeted therapies prevent tumor growth and spread by interfering with certain molecules that play a role in tumor growth and progression.
A better understanding of the molecular changes that have led to tumor growth in breast cancer in recent years has led to the discovery of new compounds that are under investigation and are being studied for the treatment of this disease.
Hiç yorum yok:
Yorum Gönder